Get notified of page updates
Education > XRAY > Hereditary Cancer Risk

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search by Topic Submit an Article for Review

Hereditary Cancer Risk

51 through 60 of 136

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Daily high-dose aspirin taken for at least 2 years reduces the risk of colorectal cancer but not other cancers in people with Lynch syndrome

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with Lynch syndrome

Research has shown that daily aspirin use can reduce the risk of colon and other cancers. The Cancer Prevention Program 2 (CaPP2) study looked at the effect of daily aspirin in patients with Lynch syndrome. After 10 years of follow-up, the results showed that taking daily aspirin for two years reduced the frequency of colon cancer in patients with Lynch syndrome, and importantly, did not result in an increase in side-effects or complications. No benefit was seen for other Lynch syndrome-related cancers, including endometrial cancer. (5/17/21)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: High

View Related Clinical Trials

Update : Cancer disparities: Colorectal cancer in African Americans

Relevance: Medium-High

Strength of Science: High

View Related Clinical Trials

Most relevant for: African Americans concerned about colorectal cancer

The American Association for Cancer Research (AACR) released a 2020 report about cancer disparities among racial and ethnic groups in the United States. In this XRAY review, we highlight data from the report about the burden of colorectal cancer in African Americans, who have the highest rates of diagnosis and death related to the disease among all racial and ethnic groups. (Posted 4/27/21)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Patient outcomes and experiences of going flat

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Women considering mastectomy without breast reconstruction.

Some patients with early-stage breast cancer or those considering risk-reducing surgery may choose mastectomy without reconstruction. This is often referred to as “going flat.” The results of this study suggest that surgeons play a significant role in supporting a patient’s decision to go flat. (3/23/2021)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Body Mass Index (BMI) may affect how well aspirin use protects against colorectal and ovarian cancer

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People concerned about their risk of colorectal or ovarian cancer.

This study looked at the impact of daily aspirin use on the risk for many types of cancers and whether this effect can be modified by risk factors such as obesity, smoking, physical inactivity or a family history of cancer. Daily aspirin use: 

  • lowered the risk for colorectal cancer, but this effect was lost as Body Mass Index (BMI) increased.
  • lowered the risk of ovarian cancer risk among obese women.
  • offered little or no protection against breast, endometrial or advanced prostate cancer.

(posted 3/19/21)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Study : Breastfeeding may lower risk of ovarian cancer in women with BRCA mutations

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: Women considering breastfeeding who have inherited BRCA mutations.

Data from a large-scale study suggests that breastfeeding may protect against ovarian cancer in women with inherited mutations in BRCA1 or BRCA2. (1/28/21)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Study : Women support delayed removal of ovaries

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: Women at high risk of ovarian cancer who are considering undergoing risk-reducing surgery.

Risk-reducing early removal of fallopian tubes followed by removal of ovaries at a later date was acceptable to women at high risk of ovarian cancer due to an inherited mutation in a recent study. This was especially true for women worried about sexual dysfunction associated with surgical menopause. (12/24/20)

Read More

Relevance: Medium

Strength of Science: Medium

Research Timeline: Post Approval

View Related Clinical Trials

Study : Inherited gene mutations found in pancreatic cancer families in Spain

Relevance: Medium

Strength of Science: Medium

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with pancreatic cancer and a family history of pancreatic or other cancers

This study looked for inherited mutations in genes known to be linked to hereditary pancreatic cancer. The results provide additional evidence that most hereditary pancreatic cancer is due to inherited mutations in genes that were previously associated with other forms of cancer. (10/29/20)

Read More

Relevance: Medium

Research Timeline: Post Approval

View Related Clinical Trials

Update : FDA updates reported harmful events linked to breast implants

Relevance: Medium

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People who have or are considering breast implants.

The FDA has updated reported cases of breast implant-associated cancer and breast implant illness. Included in this update is approval of a questionnaire that asks about quality of life and satisfaction with breast implants. (10/20/20). Note: On October 27, 2021 the FDA announced stronger guidance on breast implant safety.

Read More

Relevance: Medium-Low

Strength of Science: Medium-Low

Research Timeline: Human Research

View Related Clinical Trials

Study : Dairy milk may slightly raise breast cancer risk

Relevance: Medium-Low

Strength of Science: Medium-Low

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: Women who consume dairy or soy

Debate continues about whether consuming soy or dairy products increases breast cancer risk. This study looked at a large number of women and found no link between soy and breast cancer risk. The study did find that postmenopausal women who drank dairy milk have a small increase in breast cancer risk. (09/04/20)

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

Study : What is the risk for a new breast cancer diagnosis in the other breast for women with a BRCA1, BRCA2 or TP53 mutation?

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

Most relevant for: Women diagnosed with breast cancer who have a mutation in BRCA1, BRCA2 or TP53

For women who have been diagnosed with breast cancer, knowing their risk of breast cancer in the other (contralateral) breast can help them make decisions about surgery and screening. This study shows that women with an inherited mutation in BRCA1, BRCA2 or TP53 have an increased risk for contralateral breast cancer. This risk is highest in women with a TP53 mutation. (6/6/20)

Read More

This Portal Sponsored By:

CDC